Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

被引：87
|
作者：
Hamilton, Chad A. [1 ]
Maxwell, G. Larry [1 ]
Chemofsky, Mildred R. [1 ]
Bernstein, Sarah A. [1 ]
Farley, John H. [1 ]
Rose, G. Scott [1 ]
机构：
[1] Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Washington, DC 20307 USA
来源：
GYNECOLOGIC ONCOLOGY | 2008年 / 111卷 / 03期
关键词：
Bevacizumab; Intraperitoneal; Ovarian cancer; Ascites; Palliation;
D O I：
10.1016/j.ygyno.2008.04.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background. Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case. We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion. Intraperitoneal bevacizumab may be a useful 1001 in the palliation of malignant ascites and is worthy of further study. Published by Elsevier Inc.
引用
收藏
页码：530 / 532
页数：3
相关论文
共 50 条
  • [41] PALLIATION OF MALIGNANT ASCITES BY THE DENVER PERITONEOVENOUS SHUNT
    DOWNING, R
    BLACK, J
    WINDSOR, CWO
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 1984, 66 (05) : 340 - 343
  • [42] PERITONEOVENOUS SHUNTS FOR PALLIATION OF THE PATIENT WITH MALIGNANT ASCITES
    SCHUMACHER, DL
    SACLARIDES, TJ
    STAREN, ED
    ANNALS OF SURGICAL ONCOLOGY, 1994, 1 (05) : 378 - 381
  • [43] PERITONEOVENOUS SHUNT FOR PALLIATION OF GYNECOLOGIC MALIGNANT ASCITES
    FAUGHT, W
    KIRKPATRICK, JR
    KREPART, GV
    HEYWOOD, MS
    LOTOCKI, RJ
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1995, 180 (04) : 472 - 474
  • [44] Malignant ascites Intraperitoneal immune therapy
    Musch, Annemarie
    ONKOLOGE, 2009, 15 (09): : 943 - 943
  • [45] Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study
    Berek, J. S.
    Edwards, R. P.
    Parker, L.
    DeMars, L. R.
    Herzog, T. J.
    Lentz, S. S.
    Morris, R.
    Akerley, W. L.
    Holloway, R. W.
    Method, M.
    Plaxe, S. C.
    Walker, J. L.
    Schindler, T.
    Schulze, E.
    Krasner, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study
    Berek, Jonathan S.
    Edwards, Robert P.
    Parker, Lynn P.
    DeMars, Leslie R.
    Herzog, Thomas J.
    Lentz, Samuel S.
    Morris, Robert T.
    Akerley, Wallace L.
    Holloway, Robert W.
    Method, Michael W.
    Plaxe, Steven C.
    Walker, Joan L.
    Friccius-Quecke, Hilke
    Krasner, Carolyn N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1583 - 1589
  • [47] Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics
    Smolle, Elisabeth
    Taucher, Valentin
    Haybaeck, Johannes
    ANTICANCER RESEARCH, 2014, 34 (04) : 1553 - 1561
  • [48] Palliative Chemotherapy for Malignant Ascites Secondary to Ovarian Cancer
    Malayev, Yuliya
    Levene, Richard
    Gonzalez, Faustino
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2012, 29 (07): : 515 - 521
  • [49] INTRAPERITONEAL IMMUNOTHERAPY IN PATIENTS WITH THERAPY RESISTANT OVARIAN-CANCER ASCITES
    NOWOTNY, C
    SCHIEDER, K
    JANISCH, H
    FURLINGER, B
    MICKSCHE, M
    BLUT, 1985, 51 (03): : 177 - 177
  • [50] INTRAPERITONEAL RECOMBINANT INTERFERON-ALPHA 2B FOR RECURRENT MALIGNANT ASCITES DUE TO OVARIAN-CANCER
    BEZWODA, WR
    SEYMOUR, L
    DANSEY, R
    CANCER, 1989, 64 (05) : 1029 - 1033
12345